Gastroenterology and Hepatology from Bed to Bench

Rose CF, Amodio P, Bajaj JS, Dhiman RK, Montagnese S, Taylor-Robinson SD, et al. Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy. Journal of hepatology. 2020;73(6):1526-47.

Kubota K, Uojima H, Shao X, Iwasaki S, Hidaka H, Wada N, et al. Additional L-carnitine reduced the risk of hospitalization in patients with overt hepatic encephalopathy on rifaximin. Digestive Diseases. 2022;40(3):313-21.

Sato S, Namisaki T, Furukawa M, Saikawa S, Kawaratani H, Kaji K, et al. Effect of L‑carnitine on health‑related quality of life in patients with liver cirrhosis. Biomedical Reports. 2020;13(6):1-.

Gnoni A, Longo S, Gnoni GV, Giudetti AM. Carnitine in human muscle bioenergetics: can carnitine supplementation improve physical exercise? Molecules. 2020;25(1):182.

Hanai T, Shiraki M, Imai K, Suetugu A, Takai K, Shimizu M. Usefulness of carnitine supplementation for the complications of liver cirrhosis. Nutrients. 2020;12(7):1915.

Palmieri F, Scarcia P, Monné M. Diseases caused by mutations in mitochondrial carrier genes SLC25: a review. Biomolecules. 2020;10(4):655.

Zhou W, Li H, Huang T, Zhang Y, Wang C, Gu M. Biochemical, molecular, and clinical characterization of patients with primary carnitine deficiency via large-scale newborn screening in Xuzhou area. Frontiers in Pediatrics. 2019;7:50.

Kerner J, Hoppel CL. Fatty acid import into mitochondria. Biochimica et biophysica acta. 2000;1486 1:1-17.

Console L, Giangregorio N, Indiveri C, Tonazzi A. Carnitine/acylcarnitine translocase and carnitine palmitoyltransferase 2 form a complex in the inner mitochondrial membrane. Molecular and Cellular Biochemistry. 2014;394:307-14.

Zammit VA, Price NT, Jackson VN, Park B-s. The Role of Carnitine Acyltransferases in the Maintenance of Cell Function. Monatshefte für Chemie / Chemical Monthly. 2005;136:1299-309.

Ramsay RR, Gandour RD, Leij Fvd. Molecular enzymology of carnitine transfer and transport. Biochimica et biophysica acta. 2001;1546 1:21-43.

Ramsay RR. The carnitine acyltransferases: modulators of acyl-CoA-dependent reactions. Biochemical Society transactions. 2000;28 2:182-6.

Jogl G, Hsiao YS, Tong L. Structure and Function of Carnitine Acyltransferases. Annals of the New York Academy of Sciences. 2004;1033.

Cl H, editor Carnitine and carnitine palmitoyltransferase in fatty acid oxidation and ketosis1982.

Hoppel CL. Carnitine and carnitine palmitoyltransferase in fatty acid oxidation and ketosis. Federation proceedings. 1982;41 12:2853-7.

Kispál G, Csekó J, Alkonyi I, Sandor A. Isolation and characterization of carnitine acetyltransferase from S. cerevisiae. Biochimica et biophysica acta. 1991;1085 2:217-22.

Chapela SP, Kriguer N, Fernández EH, Stella CA. Involvement of L-carnitine in cellular metabolism: beyond Acyl-CoA transport. Mini reviews in medicinal chemistry. 2009;9 13:1518-26.

Bremer J. Carnitine--metabolism and functions. Physiol Rev. 1983;63(4):1420-80.

Adeva-Andany MM, Carneiro-Freire N, Seco-Filgueira M, Fernández-Fernández C, Mouriño-Bayolo D. Mitochondrial β-oxidation of saturated fatty acids in humans. Mitochondrion. 2019;46:73-90.

Pande SV. A mitochondrial carnitine acylcarnitine translocase system. Proceedings of the National Academy of Sciences of the United States of America. 1975;72 3:883-7.

Roe DS, Roe CR, Brivet Ml, Sweetman L. Evidence for a short-chain carnitine-acylcarnitine translocase in mitochondria specifically related to the metabolism of branched-chain amino acids. Molecular genetics and metabolism. 2000;69 1:69-75.

Murthy MSR, Pande SV. Mechanism of carnitine acylcarnitine translocase-catalyzed import of acylcarnitines into mitochondria. The Journal of biological chemistry. 1984;259 14:9082-9.

Fritz IB, Marquis NR. The role of acylcarnitine esters and carnitine palmityltransferase in the transport of fatty acyl groups across mitochondrial membranes. Proc Natl Acad Sci U S A. 1965;54(4):1226-33.

Roe CR, Hoppel CL, Stacey TE, Chalmers RA, Tracey BM, Millington DS. Metabolic response to carnitine in methylmalonic aciduria. An effective strategy for elimination of propionyl groups. Arch Dis Child. 1983;58(11):916-20.

Millington DS, Roe CR, Maltby DA. Characterization of new diagnostic acylcarnitines in patients with beta-ketothiolase deficiency and glutaric aciduria type I using mass spectrometry. Biomed Environ Mass Spectrom. 1987;14(12):711-6.

Röschinger W, Millington DS, Gage DA, Huang ZH, Iwamoto T, Yano S, et al. 3-Hydroxyisovalerylcarnitine in patients with deficiency of 3-methylcrotonyl CoA carboxylase. Clin Chim Acta. 1995;240(1):35-51.

Jakobs BS, Wanders RJ. Fatty acid beta-oxidation in peroxisomes and mitochondria: the first, unequivocal evidence for the involvement of carnitine in shuttling propionyl-CoA from peroxisomes to mitochondria. Biochem Biophys Res Commun. 1995;213(3):1035-41.

Ramsay RR, Arduini A. The carnitine acyltransferases and their role in modulating acyl-CoA pools. Arch Biochem Biophys. 1993;302(2):307-14.

Röschinger W, Muntau AC, Duran M, Dorland L, L IJ, Wanders RJ, Roscher AA. Carnitine-acylcarnitine translocase deficiency: metabolic consequences of an impaired mitochondrial carnitine cycle. Clin Chim Acta. 2000;298(1-2):55-68.

Fraser F, Corstorphine CG, Zammit VA. Evidence that both the acyl-CoA- and malonyl-CoA binding sites of mitochondrial overt carnitine palmitoyltransferase (CPT I) are exposed on the cytosolic face of the outer membrane. Biochemical Society transactions. 1996;24 2:184S.

Masterson C, Wood C. Carnitine palmitoyltransferases in pea leaf chloroplasts: partial purification, location, and properties. Botany. 2000;78:328-35.

Zammit VA. Increased sensitivity of carnitine palmitoyltransferase I activity to malonyl-CoA inhibition after preincubation of intact rat liver mitochondria with micromolar concentrations of malonyl-CoA in vitro. The Biochemical journal. 1983;210 3:953-6.

López-Viñas E, Bentebibel A, Gurunathan C, Morillas M, de Arriaga D, Serra D, et al. Definition by Functional and Structural Analysis of Two Malonyl-CoA Sites in Carnitine Palmitoyltransferase 1A*. Journal of Biological Chemistry. 2007;282:18212 - 24.

Jackson VN, Cameron JM, Zammit VA, Price NT. Sequencing and functional expression of the malonyl-CoA-sensitive carnitine palmitoyltransferase from Drosophila melanogaster. The Biochemical journal. 1999;341 ( Pt 3):483-9.

Cohen I, Kohl C, McGarry JD, Girard J, Prip-Buus C. The N-terminal Domain of Rat Liver Carnitine Palmitoyltransferase 1 Mediates Import into the Outer Mitochondrial Membrane and Is Essential for Activity and Malonyl-CoA Sensitivity*. The Journal of Biological Chemistry. 1998;273:29896 - 904.

Swanson S, Foster DW, McGarry JD, Brown NF. Roles of the N- and C-terminal domains of carnitine palmitoyltransferase I isoforms in malonyl-CoA sensitivity of the enzymes: insights from expression of chimaeric proteins and mutation of conserved histidine residues. The Biochemical journal. 1998;335 ( Pt 3):513-9.

Pan Y, Cohen I, Guillerault F, Fève B, Girard J, Prip-Buus C. The Extreme C Terminus of Rat Liver Carnitine Palmitoyltransferase I Is Not Involved in Malonyl-CoA Sensitivity but in Initial Protein Folding*. The Journal of Biological Chemistry. 2002;277:47184 - 9.

Woldegiorgis G, Dai J, Arvidson DN. Structure-Function Studies with the Mitochondrial Carnitine Palmitoyltransferases I and II. Monatshefte für Chemie / Chemical Monthly. 2005;136:1325-40.

D., editor Malonyl-CoA and carnitine palmitoyltransferase I : an expanding partnership2009.

Jackson VN, Zammit VA, Price NT. Identification of Positive and Negative Determinants of Malonyl-CoA Sensitivity and Carnitine Affinity within the Amino Termini of Rat Liver- and Muscle-type Carnitine Palmitoyltransferase I*. The Journal of Biological Chemistry. 2000;275:38410 - 6.

Kolodziej MP, Zammit VA. Sensitivity of inhibition of rat liver mitochondrial outer-membrane carnitine palmitoyltransferase by malonyl-CoA to chemical- and temperature-induced changes in membrane fluidity. The Biochemical journal. 1990;272 2:421-5.

Hardie DG, Carling D. The AMP-activated protein kinase--fuel gauge of the mammalian cell? European journal of biochemistry. 1997;246 2:259-73.

Wolfgang MJ, Kurama T, Dai Y, Suwa A, Asaumi M, Matsumoto Si, et al. The brain-specific carnitine palmitoyltransferase-1c regulates energy homeostasis. Proceedings of the National Academy of Sciences of the United States of America. 2006;103 19:7282-7.

Eaton S, Bartlett K, Pourfarzam M. Mammalian mitochondrial beta-oxidation. Biochem J. 1996;320 ( Pt 2)(Pt 2):345-57.

Console L, Giangregorio N, Indiveri C, Tonazzi A. Carnitine/acylcarnitine translocase and carnitine palmitoyltransferase 2 form a complex in the inner mitochondrial membrane. Mol Cell Biochem. 2014;394(1-2):307-14.

Morillas M, López-Viñas E, Valencia A, Serra D, Gómez-Puertas P, Hegardt FG, Asins G. Structural model of carnitine palmitoyltransferase I based on the carnitine acetyltransferase crystal. Biochem J. 2004;379(Pt 3):777-84.

Joshi PR, Zierz S. Muscle Carnitine Palmitoyltransferase II (CPT II) Deficiency: A Conceptual Approach. Molecules. 2020;25(8).

Gross CJ, Henderson LM. Absorption of D- and L-carnitine by the intestine and kidney tubule in the rat. Biochim Biophys Acta. 1984;772(2):209-19.

Huth PJ, Shug AL. Properties of carnitine transport in rat kidney cortex slices. Biochimica et Biophysica Acta (BBA)-Biomembranes. 1980;602(3):621-34.

Huth PJ, Schmidt MJ, Hall PV, Fariello RG, Shug AL. The uptake of carnitine by slices of rat cerebral cortex. J Neurochem. 1981;36(2):715-23.

Mroczkowska JE, Galla HJ, Nalecz MJ, Nalecz KA. Evidence for an asymmetrical uptake of L-carnitine in the blood-brain barrier in vitro. Biochem Biophys Res Commun. 1997;241(1):127-31.

Prasad PD, Huang W, Ramamoorthy S, Carter AL, Leibach FH, Ganapathy V. Sodium-dependent carnitine transport in human placental choriocarcinoma cells. Biochim Biophys Acta. 1996;1284(1):109-17.

Stieger B, O'Neill B, Krähenbühl S. Characterization of L-carnitine transport by rat kidney brush-border-membrane vesicles. Biochem J. 1995;309 ( Pt 2)(Pt 2):643-7.

Inano A, Sai Y, Kato Y, Tamai I, Ishiguro M, Tsuji A. Functional regions of organic cation/carnitine transporter OCTN2 (SLC22A5): roles in carnitine recognition. Drug metabolism and pharmacokinetics. 2004;19 3:180-9.

Tamai I, Ohashi R, Nezu J, Yabuuchi H, Oku A, Shimane M, et al. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem. 1998;273(32):20378-82.

Grube M, Schwabedissen HEUMz, Präger D, Haney J, Möritz K-U, Meissner K, et al. Uptake of Cardiovascular Drugs Into the Human Heart. Circulation. 2006;113(8):1114-22.

Ohashi R, Tamai I, Nezu Ji J, Nikaido H, Hashimoto N, Oku A, et al. Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol Pharmacol. 2001;59(2):358-66.

Wagner CA, Lükewille U, Kaltenbach S, Moschen I, Bröer A, Risler T, et al. Functional and pharmacological characterization of human Na+-carnitine cotransporter hOCTN2. American Journal of Physiology-Renal Physiology. 2000;279(3):F584-F91.

Sekine T, Kusuhara H, Utsunomiya-Tate N, Tsuda M, Sugiyama Y, Kanai Y, Endou H. Molecular cloning and characterization of high-affinity carnitine transporter from rat intestine. Biochem Biophys Res Commun. 1998;251(2):586-91.

Hanada K, Nakata T, Ouchi M, Ohtsubo M, Isono M, Morita A, et al. Identification of carnitine transporter CT1 binding protein lin-7 in nervous system. 2016;43:31-8.

Palmieri F, Pierri CL. Mitochondrial metabolite transport. Essays Biochem. 2010;47:37-52.

Palmieri F. The mitochondrial transporter family SLC25: identification, properties and physiopathology. Mol Aspects Med. 2013;34(2-3):465-84.

Palmieri F, Scarcia P, Monné M. Diseases Caused by Mutations in Mitochondrial Carrier Genes SLC25: A Review. Biomolecules. 2020;10(4).

Tonazzi A, Giangregorio N, Console L, Palmieri F, Indiveri C. The Mitochondrial Carnitine Acyl-carnitine Carrier (SLC25A20): Molecular Mechanisms of Transport, Role in Redox Sensing and Interaction with Drugs. Biomolecules. 2021;11(4).

Agrimi G, Russo A, Scarcia P, Palmieri F. The human gene SLC25A17 encodes a peroxisomal transporter of coenzyme A, FAD and NAD+. Biochem J. 2012;443(1):241-7.

Ling P, Lee DJ, Yoshida EM, Sirrs S. Carnitine deficiency presenting with encephalopathy and hyperammonemia in a patient receiving chronic enteral tube feeding: a case report. Journal of Medical Case Reports. 2012;6(1):227.

Limketkai BN, Zucker SD. Hyperammonemic encephalopathy caused by carnitine deficiency. J Gen Intern Med. 2008;23(2):210-3.

Hanai T, Shiraki M, Imai K, Suetugu A, Takai K, Shimizu M. Usefulness of Carnitine Supplementation for the Complications of Liver Cirrhosis. Nutrients. 2020;12(7).

Fu L, Huang M, Chen S. Primary carnitine deficiency and cardiomyopathy. Korean Circ J. 2013;43(12):785-92.

Waber LJ, Valle D, Neill C, DiMauro S, Shug A. Carnitine deficiency presenting as familial cardiomyopathy: a treatable defect in carnitine transport. J Pediatr. 1982;101(5):700-5.

Zhang W, Miao J, Zhang G, Liu R, Zhang D, Wan Q, et al. Muscle carnitine deficiency: adult onset lipid storage myopathy with sensory neuropathy. Neurol Sci. 2010;31(1):61-4.

Di Mauro S, Trevisan C, Hays A. Disorders of lipid metabolism in muscle. Muscle Nerve. 1980;3(5):369-88.

Pons R, De Vivo DC. Primary and secondary carnitine deficiency syndromes. J Child Neurol. 1995;10 Suppl 2:S8-24.

Mesmer OT, Lo TC. Hexose transport properties of myoblasts isolated from a patient with suspected muscle carnitine deficiency. Biochem Cell Biol. 1990;68(12):1372-9.

Almannai M, Alfadhel M, El-Hattab AW. Carnitine Inborn Errors of Metabolism. Molecules. 2019;24(18).

El-Hattab AW, Scaglia F. Disorders of carnitine biosynthesis and transport. Mol Genet Metab. 2015;116(3):107-12.

Celestino-Soper PB, Shaw CA, Sanders SJ, Li J, Murtha MT, Ercan-Sencicek AG, et al. Use of array CGH to detect exonic copy number variants throughout the genome in autism families detects a novel deletion in TMLHE. Hum Mol Genet. 2011;20(22):4360-70.

Rashidi-Nezhad A, Talebi S, Saebnouri H, Akrami SM, Reymond A. The effect of homozygous deletion of the BBOX1 and Fibin genes on carnitine level and acyl carnitine profile. BMC Med Genet. 2014;15:75.

Garavaglia B, Uziel G, Dworzak F, Carrara F, DiDonato S. Primary carnitine deficiency: heterozygote and intrafamilial phenotypic variation. Neurology. 1991;41(10):1691-3.

Stanley CA, DeLeeuw S, Coates PM, Vianey-Liaud C, Divry P, Bonnefont JP, et al. Chronic cardiomyopathy and weakness or acute coma in children with a defect in carnitine uptake. Ann Neurol. 1991;30(5):709-16.

Tein I, De Vivo DC, Ranucci D, DiMauro S. Skin fibroblast carnitine uptake in secondary carnitine deficiency disorders. J Inherit Metab Dis. 1993;16(1):135-46.

Esser V, Britton CH, Weis BC, Foster DW, McGarry JD. Cloning, sequencing, and expression of a cDNA encoding rat liver carnitine palmitoyltransferase I. Direct evidence that a single polypeptide is involved in inhibitor interaction and catalytic function. J Biol Chem. 1993;268(8):5817-22.

Stanley CA, Treem WR, Hale DE, Coates PM. A genetic defect in carnitine transport causing primary carnitine deficiency. Prog Clin Biol Res. 1990;321:457-64.

Tein I, De Vivo DC, Bierman F, Pulver P, De Meirleir LJ, Cvitanovic-Sojat L, et al. Impaired skin fibroblast carnitine uptake in primary systemic carnitine deficiency manifested by childhood carnitine-responsive cardiomyopathy. Pediatr Res. 1990;28(3):247-55.

Treem WR, Stanley CA, Finegold DN, Hale DE, Coates PM. Primary carnitine deficiency due to a failure of carnitine transport in kidney, muscle, and fibroblasts. N Engl J Med. 1988;319(20):1331-6.

Bennett MJ, Hale DE, Pollitt RJ, Stanley CA, Variend S. Endocardial fibroelastosis and primary carnitine deficiency due to a defect in the plasma membrane carnitine transporter. Clin Cardiol. 1996;19(3):243-6.

Rinaldo P, Stanley CA, Hsu BY, Sanchez LA, Stern HJ. Sudden neonatal death in carnitine transporter deficiency. J Pediatr. 1997;131(2):304-5.

Rodrigues Pereira R, Scholte HR, Luyt-Houwen IE, Vaandrager-Verduin MH. Cardiomyopathy associated with carnitine loss in kidneys and small intestine. Eur J Pediatr. 1988;148(3):193-7.

Han L, Wang F, Wang Y, Ye J, Qiu W, Zhang H, et al. Analysis of genetic mutations in Chinese patients with systemic primary carnitine deficiency. European Journal of Medical Genetics. 2014;57(10):571-5.

Jakoby Mt, Jaju A, Marsh A, Wilber A. Maternal Primary Carnitine Deficiency and a Novel Solute Carrier Family 22 Member 5 (SLC22A5) Mutation. J Investig Med High Impact Case Rep. 2021;9:23247096211019543.

Burwinkel B, Kreuder J, Schweitzer S, Vorgerd M, Gempel K, Gerbitz KD, Kilimann MW. Carnitine transporter OCTN2 mutations in systemic primary carnitine deficiency: a novel Arg169Gln mutation and a recurrent Arg282ter mutation associated with an unconventional splicing abnormality. Biochem Biophys Res Commun. 1999;261(2):484-7.

Tan J, Chen D, Li Z, Yuan D, Liu B, Yan T, et al. [SLC22A5 gene mutation analysis and prenatal diagnosis for a family with primary carnitine deficiency]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2019;36(7):690-3.

Zhang Y, Li H, Liu J, Yan H, Liu Q, Wei X, et al. Molecular investigation in Chinese patients with primary carnitine deficiency. Mol Genet Genomic Med. 2019;7(9):e901.

Liammongkolkul S, Boonyawat B, Vijarnsorn C, Tim-Aroon T, Wasant P, Vatanavicharn N. Phenotypic and molecular features of Thai patients with primary carnitine deficiency. Pediatr Int. 2023;65(1):e15404.

Longo N. Primary Carnitine Deficiency and Newborn Screening for Disorders of the Carnitine Cycle. Ann Nutr Metab. 2016;68 Suppl 3:5-9.

Rasmussen J, Dunø M, Lund AM, Steuerwald U, Hansen S-H, Joensen HD, et al. Increased risk of sudden death in untreated primary carnitine deficiency. Journal of Inherited Metabolic Disease. 2020;43(2):290-6.

Angelini C, Vergani L, Martinuzzi A. Clinical and Biochemical Aspects of Carnitine Deficiency and Insufficiency: Transport Defects and Inborn Errors of β-Oxidation. Critical Reviews in Clinical Laboratory Sciences. 1992;29(3-4):217-42.

Breningstall GN. Carnitine deficiency syndromes. Pediatr Neurol. 1990;6(2):75-81.

Yan S, Yang XF, Liu HL, Fu N, Ouyang Y, Qing K. Long-chain acyl-CoA synthetase in fatty acid metabolism involved in liver and other diseases: an update. World J Gastroenterol. 2015;21(12):3492-8.

Watkins PA, Maiguel D, Jia Z, Pevsner J. Evidence for 26 distinct acyl-coenzyme A synthetase genes in the human genome. J Lipid Res. 2007;48(12):2736-50.

McGarry JD, Brown NF. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem. 1997;244(1):1-14.

Pande SV, Brivet M, Slama A, Demaugre F, Aufrant C, Saudubray JM. Carnitine-acylcarnitine translocase deficiency with severe hypoglycemia and auriculo ventricular block. Translocase assay in permeabilized fibroblasts. J Clin Invest. 1993;91(3):1247-52.

Palmieri F. Diseases caused by defects of mitochondrial carriers: A review. Biochimica et Biophysica Acta (BBA) - Bioenergetics. 2008;1777(7):564-78.

Fukushima T, Kaneoka H, Yasuno T, Sasaguri Y, Tokuyasu T, Tokoro K, et al. Three novel mutations in the carnitine-acylcarnitine translocase (CACT) gene in patients with CACT deficiency and in healthy individuals. J Hum Genet. 2013;58(12):788-93.

Costa C, Costa J, Nuoffer J-M, Slama A, Boutron A, Saudubray J-M, et al. Identification of the molecular defect in a severe case of carnitine-acylcarnitine carrier deficiency. Journal of inherited metabolic disease. 1999;22:267-70.

Bougneres PF, Saudubray JM, Marsac C, Bernard O, Odievre M, Girard JR. Decreased ketogenesis due to deficiency of hepatic carnitine acyl transferase. N Engl J Med. 1980;302(2):123-4.

Demaugre F, Bonnefont JP, Mitchell G, Nguyen-Hoang N, Pelet A, Rimoldi M, et al. Hepatic and muscular presentations of carnitine palmitoyl transferase deficiency: two distinct entities. Pediatr Res. 1988;24(3):308-11.

Haworth JC, Demaugre F, Booth FA, Dilling LA, Moroz SP, Seshia SS, et al. Atypical features of the hepatic form of carnitine palmitoyltransferase deficiency in a Hutterite family. J Pediatr. 1992;121(4):553-7.

Tein I, Demaugre F, Bonnefont JP, Saudubray JM. Normal muscle CPT1 and CPT2 activities in hepatic presentation patients with CPT1 deficiency in fibroblasts. Tissue specific isoforms of CPT1? J Neurol Sci. 1989;92(2-3):229-45.

Ogawa E, Kanazawa M, Yamamoto S, Ohtsuka S, Ogawa A, Ohtake A, et al. Expression analysis of two mutations in carnitine palmitoyltransferase IA deficiency. J Hum Genet. 2002;47(7):342-7.

DiMauro S, DiMauro PM. Muscle carnitine palmityltransferase deficiency and myoglobinuria. Science. 1973;182(4115):929-31.

Coates PM, Tanaka K. Molecular basis of mitochondrial fatty acid oxidation defects. J Lipid Res. 1992;33(8):1099-110.

Demaugre F, Bonnefont JP, Colonna M, Cepanec C, Leroux JP, Saudubray JM. Infantile form of carnitine palmitoyltransferase II deficiency with hepatomuscular symptoms and sudden death. Physiopathological approach to carnitine palmitoyltransferase II deficiencies. J Clin Invest. 1991;87(3):859-64.

Finocchiaro G, Taroni F, Rocchi M, Martin AL, Colombo I, Tarelli GT, DiDonato S. cDNA cloning, sequence analysis, and chromosomal localization of the gene for human carnitine palmitoyltransferase. Proc Natl Acad Sci U S A. 1991;88(2):661-5.

Demaugre F, Bonnefont JP, Cepanec C, Scholte J, Saudubray JM, Leroux JP. Immunoquantitative analysis of human carnitine palmitoyltransferase I and II defects. Pediatr Res. 1990;27(5):497-500.

Yang BZ, Ding JH, Roe D, Dewese T, Day DW, Roe CR. A novel mutation identified in carnitine palmitoyltransferase II deficiency. Mol Genet Metab. 1998;63(2):110-5.

Wieser T, Deschauer M, Olek K, Hermann T, Zierz S. Carnitine palmitoyltransferase II deficiency: molecular and biochemical analysis of 32 patients. Neurology. 2003;60(8):1351-3.

Kaufmann P, DiMauro S. Carnitine palmitoyltransferase II deficiency: Diagnosis by molecular analysis of blood. Molecular and Cellular Biochemistry. 1997;174(1):237-9.

Yasuno T, Kaneoka H, Tokuyasu T, Aoki J, Yoshida S, Takayanagi M, et al. Mutations of carnitine palmitoyltransferase II (CPT II) in Japanese patients with CPT II deficiency. Clin Genet. 2008;73(5):496-501.

Spiegel R, Shaag A, Gutman A, Korman SH, Saada A, Elpeleg O, Shalev SA. Severe infantile type of carnitine palmitoyltransferase II (CPT II) deficiency due to homozygous R503C mutation. Journal of Inherited Metabolic Disease. 2007;30(2):266-.

Yang B-Z, Ding J-H, Roe D, Dewese T, Day DW, Roe CR. A Novel Mutation Identified in Carnitine Palmitoyltransferase II Deficiency. Molecular Genetics and Metabolism. 1998;63(2):110-5.

Montagnese S, Russo FP, Amodio P, Burra P, Gasbarrini A, Loguercio C, et al. Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Digestive and liver disease. 2019;51(2):190-205.

Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. Journal of Hepatology. 2015;62(2):437-47.

Jayakumar AR, Rao KVR, Norenberg MD. Neuroinflammation in hepatic encephalopathy: mechanistic aspects. Journal of clinical and experimental hepatology. 2015;5:S21-S8.

Sepehrinezhad A, Zarifkar A, Namvar G, Shahbazi A, Williams R. Astrocyte swelling in hepatic encephalopathy: molecular perspective of cytotoxic edema. Metabolic brain disease. 2020;35:559-78.

Romero-Gómez M, Boza F, García-Valdecasas MS, García E, Aguilar-Reina J. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Official journal of the American College of Gastroenterology| ACG. 2001;96(9):2718-23.

Taylor L, Liu X, Newsome W, Shapiro RA, Srinivasan M, Curthoys NP. Isolation and characterization of the promoter region of the rat kidney-type glutaminase gene. Biochimica et Biophysica Acta (BBA)-Gene Structure and Expression. 2001;1518(1-2):132-6.

Romero-Gómez M, Jover M, Del Campo JA, Royo JL, Hoyas E, Galán JJ, et al. Variations in the promoter region of the glutaminase gene and the development of hepatic encephalopathy in patients with cirrhosis: a cohort study. Annals of internal medicine. 2010;153(5):281-8.

Romero-Gómez M. Role of phosphate-activated glutaminase in the pathogenesis of hepatic encephalopathy. Metabolic brain disease. 2005;20:319-25.

Sepehrinezhad A, Shahbazi A, Sahab Negah S, Stolze Larsen F. New Insight Into Mechanisms of Hepatic Encephalopathy: An Integrative Analysis Approach to Identify Molecular Markers and Therapeutic Targets. Bioinformatics and biology insights. 2023;17:11779322231155068.

Dai H, Jia G, Wang W, Liang C, Han S, Chu M, Mei X. Genistein inhibited ammonia induced astrocyte swelling by inhibiting NF-κB activation-mediated nitric oxide formation. Metabolic Brain Disease. 2017;32(3):841-8.

Chen F, Hori T, Ohashi N, Baine A-M, Eckman CB, Nguyen JH. Occludin is regulated by epidermal growth factor receptor activation in brain endothelial cells and brains of mice with acute liver failure. Hepatology. 2011;53(4):1294-305.

van der Laan M, Bohnert M, Wiedemann N, Pfanner N. Role of MINOS in mitochondrial membrane architecture and biogenesis. Trends in cell biology. 2012;22(4):185-92.

Kishita Y, Shimura M, Kohda M, Akita M, Imai‐Okazaki A, Yatsuka Y, et al. A novel homozygous variant in MICOS13/QIL1 causes hepato‐encephalopathy with mitochondrial DNA depletion syndrome. Molecular genetics & genomic medicine. 2020;8(10):e1427.

Gödiker J, Grüneberg M, DuChesne I, Reunert J, Rust S, Westermann C, et al. QIL1-dependent assembly of MICOS complex–lethal mutation in C19ORF70 resulting in liver disease and severe neurological retardation. Journal of human genetics. 2018;63(6):707-16.

Desjardins P, Rao KR, Michalak A, Rose C, Butterworth RF. Effect of portacaval anastomosis on glutamine synthetase protein and gene expression in brain, liver and skeletal muscle. Metabolic brain disease. 1999;14:273-80.

Toris GT, Bikis CN, Tsourouflis GS, Theocharis SE. Hepatic encephalopathy: an updated approach from pathogenesis to treatment. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 2011;17(2):RA53.

Tokatli A, Coşkun T, Özalp İ. Fifteen years' experience with 212 hyperammonaemic cases at a metabolic unit. Journal of inherited metabolic disease. 1991;14:698-706.

Engel A, Rebouche C. Carnitine metabolism and inborn errors. Journal of inherited metabolic disease. 1984;7(Suppl 1):38-43.

Limketkai BN, Zucker SD. Hyperammonemic encephalopathy caused by carnitine deficiency. Journal of general internal medicine. 2008;23:210-3.

Kanamori K, Ross BD, Chung JC, Kuo EL. Severity of hyperammonemic encephalopathy correlates with brain ammonia level and saturation of glutamine synthetase in vivo. Journal of neurochemistry. 1996;67(4):1584-94.

Zwirner K, Thiel C, Thiel K, Morgalla MH, Königsrainer A, Schenk M. Extracellular brain ammonia levels in association with arterial ammonia, intracranial pressure and the use of albumin dialysis devices in pigs with acute liver failure. Metabolic brain disease. 2010;25:407-12.

Jayakumar AR, Valdes V, Norenberg MD. The Na–K–Cl cotransporter in the brain edema of acute liver failure. Journal of hepatology. 2011;54(2):272-8.

Camacho J, Rioseco-Camacho N. Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome. 2020.

Colombo J. Enzymatic disturbances in the urea cycle. Monatsschrift fur Kinderheilkunde. 1969;117(1):29-31.

Häberle J, Boddaert N, Burlina A, Chakrapani A, Dixon M, Huemer M, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet journal of rare diseases. 2012;7:1-30.

Häberle J, Rubio V. Hyperammonemias and related disorders. Physician's Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases: Springer; 2013. p. 47-62.

Baumgartner MR, Rabier D, Nassogne M-C, Dufier J-L, Padovani J-P, Kamoun P, et al. Δ 1-pyrroline-5-carboxylate synthase deficiency: neurodegeneration, cataracts and connective tissue manifestations combined with hyperammonaemia and reduced ornithine, citrulline, arginine and proline. European journal of pediatrics. 2005;164:31-6.

van Karnebeek C, Häberle J. Carbonic anhydrase VA deficiency. 2021.

de Koning TJ. Amino acid synthesis deficiencies. Journal of inherited metabolic disease. 2017;40(4):609-20.

Maines E, Piccoli G, Pascarella A, Colucci F, Burlina AB. Inherited hyperammonemias: a Contemporary view on pathogenesis and diagnosis. Expert Opinion on Orphan Drugs. 2018;6(2):105-16.

Romero-Gómez M, Ampuero J. Deciphering the spectrum of low-grade hepatic encephalopathy in clinical practice. Gastroenterology. 2014;146(4):887-90.

Romero-Gómez M, Ramos-Guerrero R, Grande L, de Terán LC, Corpas R, Camacho I, Bautista JD. Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy. Journal of hepatology. 2004;41(1):49-54.

Baker L, Lanz B, Andreola F, Ampuero J, Wijeyesekera A, Holmes E, Deutz N. New technologies–new insights into the pathogenesis of hepatic encephalopathy. Metabolic brain disease. 2016;31:1259-67.

Nezu J-i, Tamai I, Oku A, Ohashi R, Yabuuchi H, Hashimoto N, et al. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nature genetics. 1999;21(1):91-4.

El-Hattab AW, Li F-Y, Shen J, Powell BR, Bawle EV, Adams DJ, et al. Maternal systemic primary carnitine deficiency uncovered by newborn screening: clinical, biochemical, and molecular aspects. Genetics in Medicine. 2010;12(1):19-24.

Yang L, Huang X, Yang J, Zhou X, Huang X, Yang R. Screening and Diagnosis of Children with Primary Carnitine Deficiency in Zhejiang Province, China 中國浙江省原發性肉鹼缺乏兒童篩查與診斷. HK J Paediatr (new series). 2013;18(3):167-73.

Zhou W LH, Huang T, Zhang Y, Wang C, Gu M. Biochemical, molecular, and clinical characterization of patients with primary carnitine deficiency via large-scale newborn screening in Xuzhou area. Front Pediatr. 2019; 7: 50.

Viscomi C, Zeviani M. Strategies for fighting mitochondrial diseases. J Intern Med. 2020;287(6):665-84.

Rahman J, Rahman S. Mitochondrial medicine in the omics era. Lancet. 2018;391(10139):2560-74.

Bonnefont JP, Demaugre F, Prip-Buus C, Saudubray JM, Brivet M, Abadi N, Thuillier L. Carnitine palmitoyltransferase deficiencies. Mol Genet Metab. 1999;68(4):424-40.

Ramsay RR, Gandour RD, van der Leij FR. Molecular enzymology of carnitine transfer and transport. Biochim Biophys Acta. 2001;1546(1):21-43.

Wataya K, Akanuma J, Cavadini P, Aoki Y, Kure S, Invernizzi F, et al. Two CPT2 mutations in three Japanese patients with carnitine palmitoyltransferase II deficiency: functional analysis and association with polymorphic haplotypes and two clinical phenotypes. Hum Mutat. 1998;11(5):377-86.

Finocchiaro G, Taroni F, Rocchi M, Liras Martin A, Colombo I, Tarelli GT, DiDonato S. cDNA cloning, sequence analysis, and chromosomal localization of human carnitine palmitoyltransferase. Proc Natl Acad Sci U S A. 1991;88(23):10981.

Bonnefont JP, Taroni F, Cavadini P, Cepanec C, Brivet M, Saudubray JM, et al. Molecular analysis of carnitine palmitoyltransferase II deficiency with hepatocardiomuscular expression. Am J Hum Genet. 1996;58(5):971-8.

Taroni F, Verderio E, Fiorucci S, Cavadini P, Finocchiaro G, Uziel G, et al. Molecular characterization of inherited carnitine palmitoyltransferase II deficiency. Proc Natl Acad Sci U S A. 1992;89(18):8429-33.

Verderio E, Cavadini P, Montermini L, Wang H, Lamantea E, Finocchiaro G, et al. Carnitine palmitoyltransferase II deficiency: structure of the gene and characterization of two novel disease-causing mutations. Hum Mol Genet. 1995;4(1):19-29.

Katzir Z, Hochman B, Biro A, Rubinger DI, Feigel D, Silver J, et al. Carnitine palmitoyltransferase deficiency: an underdiagnosed condition? Am J Nephrol. 1996;16(2):162-6.

Innes AM, Seargeant LE, Balachandra K, Roe CR, Wanders RJA, Ruiter JPN, et al. Hepatic Carnitine Palmitoyltransferase I Deficiency Presenting as Maternal Illness in Pregnancy. Pediatric Research. 2000;47(1):43-.

Gobin S, Thuillier L, Jogl G, Faye A, Tong L, Chi M, et al. Functional and structural basis of carnitine palmitoyltransferase 1A deficiency. J Biol Chem. 2003;278(50):50428-34.

Cederbaum SD, Koo-McCoy S, Tein I, Hsu BY, Ganguly A, Vilain E, et al. Carnitine membrane transporter deficiency: a long-term follow up and OCTN2 mutation in the first documented case of primary carnitine deficiency. Mol Genet Metab. 2002;77(3):195-201.

Li FY, El-Hattab AW, Bawle EV, Boles RG, Schmitt ES, Scaglia F, Wong LJ. Molecular spectrum of SLC22A5 (OCTN2) gene mutations detected in 143 subjects evaluated for systemic carnitine deficiency. Hum Mutat. 2010;31(8):E1632-51.

Longo N, Amat di San Filippo C, Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet. 2006;142c(2):77-85.

Lamhonwah AM, Olpin SE, Pollitt RJ, Vianey-Saban C, Divry P, Guffon N, et al. Novel OCTN2 mutations: no genotype-phenotype correlations: early carnitine therapy prevents cardiomyopathy. Am J Med Genet. 2002;111(3):271-84.

Iacobazzi V, Invernizzi F, Baratta S, Pons R, Chung W, Garavaglia B, et al. Molecular and functional analysis of SLC25A20 mutations causing carnitine-acylcarnitine translocase deficiency. Hum Mutat. 2004;24(4):312-20.

Sekoguchi E, Sato N, Yasui A, Fukada S, Nimura Y, Aburatani H, et al. A novel mitochondrial carnitine-acylcarnitine translocase induced by partial hepatectomy and fasting. J Biol Chem. 2003;278(40):38796-802.

González-Regueiro J, Higuera-de la Tijera M, Moreno-Alcántar R, Torre A. Pathophysiology of hepatic encephalopathy and future treatment options. Revista de Gastroenterología de México (English Edition). 2019;84(2):195-203.

Malaguarnera M, Pistone G, Astuto M, Dell’Arte S, Finocchiaro G, Lo Giudice E, Pennisi G. L-Carnitine in the treatment of mild or moderate hepatic encephalopathy. Digestive Diseases. 2003;21(3):271-5.

Malaguarnera M. Acetyl-L-carnitine in hepatic encephalopathy. Metabolic brain disease. 2013;28:193-9.

Rose CF. Ammonia‐lowering strategies for the treatment of hepatic encephalopathy. Clinical Pharmacology & Therapeutics. 2012;92(3):321-31.

Görg B, Bidmon H-J, Häussinger D. Gene expression profiling in the cerebral cortex of patients with cirrhosis with and without hepatic encephalopathy. Hepatology. 2013;57(6):2436-47.

Longo N, Frigeni M, Pasquali M. Carnitine transport and fatty acid oxidation. Biochim Biophys Acta. 2016;1863(10):2422-35.

Vijay S, Patterson A, Olpin S, Henderson MJ, Clark S, Day C, et al. Carnitine transporter defect: diagnosis in asymptomatic adult women following analysis of acylcarnitines in their newborn infants. J Inherit Metab Dis. 2006;29(5):627-30.

Spiekerkoetter U, Huener G, Baykal T, Demirkol M, Duran M, Wanders R, et al. Silent and symptomatic primary carnitine deficiency within the same family due to identical mutations in the organic cation/carnitine transporter OCTN2. J Inherit Metab Dis. 2003;26(6):613-5.

Schimmenti LA, Crombez EA, Schwahn BC, Heese BA, Wood TC, Schroer RJ, et al. Expanded newborn screening identifies maternal primary carnitine deficiency. Mol Genet Metab. 2007;90(4):441-5.

Rose EC, di San Filippo CA, Ndukwe Erlingsson UC, Ardon O, Pasquali M, Longo N. Genotype-phenotype correlation in primary carnitine deficiency. Hum Mutat. 2012;33(1):118-23.

Rasmussen J, Nielsen OW, Lund AM, Køber L, Djurhuus H. Primary carnitine deficiency and pivalic acid exposure causing encephalopathy and fatal cardiac events. J Inherit Metab Dis. 2013;36(1):35-41.

Magoulas PL, El-Hattab AW. Systemic primary carnitine deficiency: an overview of clinical manifestations, diagnosis, and management. Orphanet J Rare Dis. 2012;7:68.

El-Hattab AW. Systemic Primary Carnitine Deficiency. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, et al., editors. GeneReviews(®). Seattle (WA): University of Washington, Seattle

Copyright © 1993-2023, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.; 1993.

Rubio-Gozalbo ME, Bakker JA, Waterham HR, Wanders RJ. Carnitine-acylcarnitine translocase deficiency, clinical, biochemical and genetic aspects. Mol Aspects Med. 2004;25(5-6):521-32.

Lopriore E, Gemke RJ, Verhoeven NM, Jakobs C, Wanders RJ, Roeleveld-Versteeg AB, Poll-The BT. Carnitine-acylcarnitine translocase deficiency: phenotype, residual enzyme activity and outcome. Eur J Pediatr. 2001;160(2):101-4.

Indiveri C, Iacobazzi V, Tonazzi A, Giangregorio N, Infantino V, Convertini P, et al. The mitochondrial carnitine/acylcarnitine carrier: function, structure and physiopathology. Mol Aspects Med. 2011;32(4-6):223-33.

Bennett MJ, Santani AB. Carnitine Palmitoyltransferase 1A Deficiency. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, et al., editors. GeneReviews(®). Seattle (WA): University of Washington, Seattle

Copyright © 1993-2023, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.; 1993.

Prasad C, Johnson JP, Bonnefont JP, Dilling LA, Innes AM, Haworth JC, et al. Hepatic carnitine palmitoyl transferase 1 (CPT1 A) deficiency in North American Hutterites (Canadian and American): evidence for a founder effect and results of a pilot study on a DNA-based newborn screening program. Mol Genet Metab. 2001;73(1):55-63.

Olpin SE, Allen J, Bonham JR, Clark S, Clayton PT, Calvin J, et al. Features of carnitine palmitoyltransferase type I deficiency. J Inherit Metab Dis. 2001;24(1):35-42.

Bonnefont JP, Djouadi F, Prip-Buus C, Gobin S, Munnich A, Bastin J. Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol Aspects Med. 2004;25(5-6):495-520.

Vladutiu GD, Quackenbush EJ, Hainline BE, Albers S, Smail DS, Bennett MJ. Lethal neonatal and severe late infantile forms of carnitine palmitoyltransferase II deficiency associated with compound heterozygosity for different protein truncation mutations. J Pediatr. 2002;141(5):734-6.

Vladutiu GD, Bennett MJ, Fisher NM, Smail D, Boriack R, Leddy J, Pendergast DR. Phenotypic variability among first-degree relatives with carnitine palmitoyltransferase II deficiency. Muscle Nerve. 2002;26(4):492-8.

Nance JR, Mammen AL. Diagnostic evaluation of rhabdomyolysis. Muscle Nerve. 2015;51(6):793-810.

Morris AA, Olpin SE, Brivet M, Turnbull DM, Jones RA, Leonard JV. A patient with carnitine-acylcarnitine translocase deficiency with a mild phenotype. J Pediatr. 1998;132(3 Pt 1):514-6.

Malik S, Paldiwal AA, Korday CS, Jadhav SS. Neonatal Carnitine Palmitoyltransferase II Deficiency: A Lethal Entity. J Clin Diagn Res. 2015;9(10):Sd01-2.

Deschauer M, Wieser T, Zierz S. Muscle Carnitine Palmitoyltransferase II Deficiency: Clinical and Molecular Genetic Features and Diagnostic Aspects. Archives of Neurology. 2005;62(1):37-41.

Ziats MN, Comeaux MS, Yang Y, Scaglia F, Elsea SH, Sun Q, et al. Improvement of regressive autism symptoms in a child with TMLHE deficiency following carnitine supplementation. Am J Med Genet A. 2015;167a(9):2162-7.

Nava C, Lamari F, Héron D, Mignot C, Rastetter A, Keren B, et al. Analysis of the chromosome X exome in patients with autism spectrum disorders identified novel candidate genes, including TMLHE. Transl Psychiatry. 2012;2(10):e179.

Celestino-Soper PB, Violante S, Crawford EL, Luo R, Lionel AC, Delaby E, et al. A common X-linked inborn error of carnitine biosynthesis may be a risk factor for nondysmorphic autism. Proc Natl Acad Sci U S A. 2012;109(21):7974-81.

Lee H, Kim HK, Kwon JT, Park S, Park HJ, Kim SK, et al. BBOX1 is down-regulated in maternal immune-activated mice and implicated in genetic susceptibility to human schizophrenia. Psychiatry Res. 2018;259:197-202.